BIVI חוב כולל להון BioVie

The price trajectory for BioVie Inc. (BIVI) on GURU.Markets, where the separate_debt_total_eq metric stands at 0.03, is based on the protection of unique molecules targeting cirrhosis and dementia. High FDA certification costs and patent protection create barriers to entry for new players, while a strong US lobby strengthens its position. Meanwhile, business success depends on the efficacy of trials rather than market cycles.

For BioVie Inc. (BIVI), which invests in the development of bevacitran to combat cirrhosis and Alzheimer's disease, financial stability is critical when scaling clinical trials. By analyzing the debt-to-equity ratio, an investor assesses the proportion of borrowed funds to net assets, where a declining trend confirms a reduction in default risks, while an increase indicates the aggressive use of leverage for expansion.